Islet Amyloid Polypeptide (IAPP) and Insulin Secretion

  • Peter C. Butler
  • Norman L. Eberhardt
  • Timothy D. O’Brien


Although it has been known for almost a century that there are marked abnormalities in the morphology of islets in patients with non-insulin-dependent diabetes mellitus (i.e., islet amyloid and loss of β-cell volume), interest in the cause of these abnormalities and their potential mechanistic significance in the pathogenesis of NIDDM has been subject to renewed interest recently. This interest has transpired from an increasing emphasis of the role of impaired insulin secretion vs insulin resistance in the pathogenesis of NIDDM, and the recent identification of a constitutive peptide present in islet amyloid, islet amyloid polypeptide (IAPP). In this chapter, we briefly review the epidemiology and the islet morphology in NIDDM before focusing on the molecular properties of amyloid in general and IAPP in particular. Finally, we focus on potential mechanisms of islet amyloidosis and propose a hypothetical model that invokes a central role for IAPP induced amyloidosis in pathogenesis in NIDDM.


Insulin Secretion Amyloid Fibril Impaired Insulin Secretion Nondiabetic Subject Islet Amyloid Polypeptide 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    DeFronzo R, Deibart D. Hendler R, Felig P, Soman V: Insulin sensitivity and insulin binding to monocytes in maturity-onset diabetes. J Clin Invest 63:939–946, 1979.CrossRefGoogle Scholar
  2. 2.
    Robertson RP, Porte D: The glucose receptor. A defective mechanism in diabetes mellitus distinct from the beta adrenergic receptor. J Clin Invest 52:870–976, 1973.CrossRefGoogle Scholar
  3. 3.
    Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH: The natural history of impaired glucose tolerance in the Pina Indians. N Engl J Med 319:1500–1506, 1988.CrossRefGoogle Scholar
  4. 4.
    Fitzgerald MG, Malins JM, O’Sullivan DJ, Wall M: Effect of sex and parity on the incidence of diabetes mellitus. Quart J Med 30:57–70, 1961.Google Scholar
  5. 5.
    Conn J, Fajans S: Symposium on diabetes: Influence of adrenal cortisol steroids on carbohydrate metabolism in man. Metabolism 5:114–120, 1956.Google Scholar
  6. 6.
    Butler PC, Kryshak EJ, Rizza RA: Mechanism of growth hormone-induced postprandial carbohydrate intolerance in humans. Am J Physiol 260 (Endocrinol Metab 23):E513–E520, 1991.Google Scholar
  7. 7.
    Eisenbarth GS: Type 1 diabetes mellitus: A chronic autoimmune disease. N Engl J Med 314:1360–1368, 1986.CrossRefGoogle Scholar
  8. 8.
    Ehrlich JC, Ratner JM: Amyloidosis of the islets of Langerhans: a restudy of islet hyalin in diabetic and nondiabetic individuals. Am J Pathol 38:49–59, 1961.Google Scholar
  9. 9.
    Niskanen LK, Uusitupa MI, Sarlund H, Siitonen O, Pyorala K: Five-year follow-up study on plasma insulin levels in newly diagnosed NIDDM patients and nondiabetic subjects. Diabetes Care 13:41–48, 1990.CrossRefGoogle Scholar
  10. 10.
    Yalow RS, Berson SA: Plasma insulin concentrations in nondiabetic and early diabetic subjects. Determination by a new sensitive immuno-assay technic. Diabetes 9:254–260, 1960.Google Scholar
  11. 11.
    Perley M, Kipnis DM: Plasma insulin responses to glucose and tolbutamide of normal weight and obese diabetic and nondiabetic subjects. Diabetes 15:867–874, 1966.Google Scholar
  12. 11a.
    Butler PC, Rizza RA: Contribution to postprandial hyperglucemia and effect on initial glucose clearance of hepatic glucose cycling in glucose-intolerant or NIDDM patients. Diabetes 40:1:73–81.Google Scholar
  13. 12.
    Eriksson J, Franssila-Kallunki A, Ekstrand A, Saloranta C, Widen E, Schalin C, Groop L: Early metabolic defects in persons at increased risk for Non-insulin-dependent diabetic mellitus. N Engl J Med 321:337–343, 1989.CrossRefGoogle Scholar
  14. 13.
    Felber JP, Golay A, Jéquier E, Curchod B, Temler E, DeFronzo RA, et al.: The metabolic consequences of long-term human obesity. Int J Obes 12:377–389, 1988.Google Scholar
  15. 14.
    Wright AD, Hill DM, Lowry C, Fraser TR: Mortality in acromegaly. Q J Med 39:1–13, 1970.Google Scholar
  16. 15.
    Wajchenberg BL, Lerne CE, Lerario AC, Toledo T, Souza IT, Rodbard HW, Rodbard D: Insulin resistance in Cushing’s syndrome. Evaluation by studies of insulin binding to erythrocytes. Diabetes 33:455–459, 1984.CrossRefGoogle Scholar
  17. 16.
    Opie EL: On the relation of chronic interstitial pancreatitis to the islands of Langerhans and to diabetes mellitus. J Exp Med 5:397, 1901.Google Scholar
  18. 17.
    Westermark P, Wilander E, Westermark GT, Johnson KH: Islet amyloid polypeptide-like immunoreactivity in the islet B cells of type 2 (non-insulin-dependent) diabetic and non-diabetic individuals. Diabetologia 30: 887, 1987.Google Scholar
  19. 18.
    Howard CF Jr: Insular amyloidosis and diabetes in Macaca nigra. Diabetes 27:357, 1978.CrossRefGoogle Scholar
  20. 19.
    Johnson KH, Stevens JB: Light and electron microscopic studies of islet amyloid in diabetic cats. Diabetes 22:81, 1973.Google Scholar
  21. 20.
    O’Brien TD, Hayden DW, O’Leary TP, Caywood DD, Johnson KH: Canine pancreatic endocrine tumors: immunohistochemical analysis of the hormone content and amyloid. Vet Pathol 24:308–314, 1987.Google Scholar
  22. 21.
    Westermark P, Wilander E: The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Diabetologia 15:417, 1978.CrossRefGoogle Scholar
  23. 22.
    Howard CF: Longitudinal studies on the development of diabetes in individual Macaca nigra. Diabetologia 29:301–306, 1986.CrossRefGoogle Scholar
  24. 23.
    de Koning EJP, Bodkin NL, Hansen BC, Clark A: Diabetes mellitus in Macaca mulatta monkeys is characterised by islet amyloidosis and reduction in beta-cell population. Diabetologia 36:378–384, 1993.CrossRefGoogle Scholar
  25. 24.
    Clark A, Holman RR, Matthews DR, Holkaday TDR, Turner RC: Non-uniform distribution of islet amyloid in the pancreas of maturity onset diabetic patients. Diabetologia 27:527, 528, 1984.CrossRefGoogle Scholar
  26. 25.
    Melato M, Antonutto G, Ferronato E: Amyloidosis of the islets of Langerhans in relation to diabetes mellitus and aging. Beitr Pathol 160:73–81, 1977.Google Scholar
  27. 26.
    Narita R, Toshimori H, Nakazato M, Kuribayashi T, Toshimori T, Kawabata K, et al.: Islet amyloid polypeptide (IAPP) and pancreatic islet amyloid deposition in diabetic and non-diabetic patients. Diabetes Res Clin Pract 15:3–14, 1992.CrossRefGoogle Scholar
  28. 27.
    Maloy AL, Longnecker DS, Greenberg ER: The relation of islet amyloid to the clinical type of diabetes. Hum Pathol 12:917–922, 1981.CrossRefGoogle Scholar
  29. 28.
    Warren S, LeCompte PM: The pancreas in diabetes mellitus. In The Pathology of Diabetes Mellitus, Lea and Febiger, Philadelphia, 1952, pp. 31–75.Google Scholar
  30. 29.
    Cohen AS, Calkins E: Electron microscopic observations on a fibrous component in amyloid of diverse origins. Nature 183:1202, 1203, 1959.CrossRefGoogle Scholar
  31. 30.
    Eanes ED, Glenner GG: X-ray diffraction studies of amyloid filaments. J Histochem Cytochem 16:673–677, 1986.CrossRefGoogle Scholar
  32. 31.
    Lansbury PT: In pursuit of the molecular structure of amyloid plaque: new technology provides unexpected and critical information. Biochemistry 31:6865–6870, 1992.CrossRefGoogle Scholar
  33. 32.
    Glenner GG, Eanes ED, Wiley CA: Amyloid fibrils formed from a segment of the pancreatic islet amyloid protein. Biochem Biophys Res Comm 155:608–614, 1988.CrossRefGoogle Scholar
  34. 33.
    Betsholtz C, Christmanson L, Engström U, Rorsman F, Jordan K, O’Brien TD, et al.: Structure of cat islet amyloid polypeptide and identification of amino acid residues of potential significance for islet amyloid formation. Diabetes 39:118–122, 1990.CrossRefGoogle Scholar
  35. 34.
    Jarrett JT, Lansbury PT: Seeding “one-dimensional crystallization” of amyloid: a pathogenic mechanism in Alzheimer’s disease and scrapie? Cell 73:1055–1058, 1993.CrossRefGoogle Scholar
  36. 35.
    Levy E, Carmen MD, Fernandez-Madrid IJ, Power MD, Lieberburg I, Van Duinen SG, Bots GT, Luyendijk W, Frangione B: Mutation of the Alzheimer’s disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 248:1124–1126, 1990.CrossRefGoogle Scholar
  37. 36.
    Drurie BGM, Perskey B, Soehnlen BJ, Grogan TM, Salmon SE: Amyloid production in human myeloma stem-cell culture, with morphological evidence of amyloid secretion by associated macrophages. N Engl J Med 307:1689–1692, 1982.CrossRefGoogle Scholar
  38. 37.
    Opie L: Cytology of the pancreas. In The Form and Function of the Cell in Health and Disease. Cowdrey EV, ed. Hoeber, New York, pp. 239–272, 1928.Google Scholar
  39. 38.
    Westermark P, Wernstedt C, Wilander E, Hayden DW, O’Brien TD, Johnson KH: Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci USA 84:3881, 1987.CrossRefGoogle Scholar
  40. 39.
    Westermark P, Wernstedt C, Wilander E, Sletten K: A novel peptide in the calcitonin gene related family as an amyloid fibril protein in the endocrine pancreas. Biochem Biophys Res Commun 140:827, 1986.CrossRefGoogle Scholar
  41. 40.
    Cooper GJS, Willis AC, Clark A, Turner RC, Sim RB, Reid KBM: Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 84:8628, 1987.CrossRefGoogle Scholar
  42. 41.
    Nakazato M, Asai J, Miyazato M, Mitsukura S, Kangawa K, Matsuo H: Isolation and identification of islet amyloid polypeptide in normal human pancreas. Regul Pept 31:179, 1990.CrossRefGoogle Scholar
  43. 42.
    Nishi M, Bell GI, Steiner DF: Islet amyloid polypeptide (amylin): no evidence of an abnormal precursor sequence in 25 type 2 (non-insulin-dependent) diabetic patients. Diabetologia 33:628–630, 1990.CrossRefGoogle Scholar
  44. 43.
    Johnson KH, O’Brien TD, Hayden DW, Jordan K, Ghobrial HKG, Mahoney WC, et al.: Immunolocalization of islet amyloid polypeptide (IAPP) in pancreatic beta cells by means of peroxidase-antiperoxidase (PAP) and protein A-gold techniques. Am J Pathol 130:1–8, 1988.Google Scholar
  45. 44.
    Lukinius A, Wilander E, Westermark GT, Engstrom U, Westermark P: Co-localization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic islets. Diabetologia 32:240, 1989.CrossRefGoogle Scholar
  46. 45.
    Leffert JD, Newgard CB, Okamoto H, Milburn JL, Luskey KL: Rat amylin: cloning and tissue specific expression in pancreatic islets. Proc Natl Acad Sci USA 86:3127, 1989.CrossRefGoogle Scholar
  47. 46.
    Clark A, Edwards CA, Ostle LR, Stutton R, Rothbard JB: Localization of islet amyloid peptide in lipofuscin bodies and secretory granules of human B-cells and in islets of type 2 diabetic subjects. Cell Tissue Res 257:179, 1989.CrossRefGoogle Scholar
  48. 47.
    Butler PC, Chou J, Carter WB, Wang Y-N, Bu B-H, et al.: Effects of meal ingestion on plasma amylin concentrations in NIDDM and nondiabetic humans. Diabetes 39:752–756, 1990.CrossRefGoogle Scholar
  49. 48.
    Hartter E, Svoboda T, Ludvik, B, Schuller M, Lell B, Kuenburg E: Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia 34:52–54, 1991.CrossRefGoogle Scholar
  50. 49.
    Mitsukawa T, Takemura J, Asai J, Nakazato M, Kangawa K, Matsuo H, et al.: Islet amyloid polypeptide response to glucose, insulin, and somatostatin analogue administration. Diabetes 39:639, 1990.CrossRefGoogle Scholar
  51. 50.
    Bretherton-Watt D, Ghetei MH, Bloom SR, Jamal H, Ferner GJM, Girgis SI, et al.: Altered islet amyloid polypeptide (amylin) gene expression is rat models of diabetes. Diabetologia 32:881, 1989.CrossRefGoogle Scholar
  52. 51.
    Betsholz C, Svensson V, Rorsman F, Engstrom U, Westermark GT, Wilander E: Islet amyloid polypeptide (IAPP): cDNA cloning and identification of an amyloidogenic region associated with the species-specific occurrence of age-related diabetes mellitus. Exp Cell Res 183:484–493, 1989.CrossRefGoogle Scholar
  53. 52.
    Westermark P, Engström U, Johnson KH, Westermark GT, Betsholtz C: Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci USA 87:5036–5040, 1990.CrossRefGoogle Scholar
  54. 53.
    O’Brien TD, Butler AE, Johnson KH, Roche PC, Butler PC: Islet amyloid polypeptide (IAPP) in human insulinomas: evidence for intracellular amyloidogenesis. Diabetes 43:329–336, 1993.CrossRefGoogle Scholar
  55. 54.
    Toshimori H, Narita R, Nakazato M, Asai J, Mitsukawa T, Kangawa K, et al.: Islet amyloid polypeptide in insulinoma and in the islet of the pancreas of non-diabetic and diabetic subjects. Virchows Archiv A Pathol Anat 418:411–417, 1991.+CrossRefGoogle Scholar
  56. 55.
    Yano BL, Hayden D W, Johnson KH: Feline insular amyloid: ultrastructural evidence for intracellular formation by nonendocrine cells. Lab Invest 45:149–156, 1981.Google Scholar
  57. 56.
    Mori H, Mori S, Saitoh Y, Moriwaki K, Iida S, Matsumoto K: Growth hormone-producing pituitary adenoma with crystal-like amyloid immuno-histochemically positive for growth hormone. Cancer 55:96–102, 1985.CrossRefGoogle Scholar
  58. 57.
    Rothman JE: Polypeptide chain binding proteins: catalysts of protein folding and related processes in cells. Cell 59:591–601, 1989.CrossRefGoogle Scholar
  59. 58.
    Hightower LE: Heat shock, stress proteins, chaperones, and proteotoxicity. Cell Press 66:191–197, 1991.Google Scholar
  60. 59.
    Ellis RJ: The molecular chaperone concept. Cell Biology 1:1–9, 1990.Google Scholar
  61. 60.
    Leighton B, Cooper GJS: Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro. Nature 335:632–635, 1988.CrossRefGoogle Scholar
  62. 61.
    Eriksson J, Nakazato M, Miyazato M, Shiomi K, Matsukura S, Groop L: Islet amyloid polypeptide plasma concentrations in individuals at increased risk of developing Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 35:291–293, 1992.CrossRefGoogle Scholar
  63. 62.
    Enoki S, Mitsukawa T, Takemura J, Nakazato M, Aburaya J, Toshimori H, et al.: Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 15:97–102, 1992.CrossRefGoogle Scholar
  64. 63.
    Ludvik B, Clodi M, Kautzky-Willer A, Capek M, Hartter E, Pacini G, Prager R: Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans. Diabetologia 36:84–87, 1993.CrossRefGoogle Scholar
  65. 64.
    Bretherton-Watt D, Gilbey SG, Ghatei MA, Beacham J, Bloom SR: Failure to establish islet amyloid polypeptide (amylin) as a circulating beta cell inhibiting hormone in man. Diabetologia 33:115–117, 1990.CrossRefGoogle Scholar
  66. 65.
    Kassir AA, Upadhyay AK, Lim TJ, Moossa AR, Olefsky JM: Lack of effect of islet amyloid polypeptide in causing insulin resistance in conscious dogs during euglycemic clamp studies. Diabetes 40:998–1004, 1991.CrossRefGoogle Scholar
  67. 66.
    Fox N, Schrementi J, Nishi M, Ohagi S, Chan SJ, Heisserman JA, et al.: Human islet amyloid polypeptide transgenic mice as a model of non-insulin-dependent diabetes mellitus (NIDDM). FEBS 323:40–44, 1993.CrossRefGoogle Scholar
  68. 67.
    Galeazza MT, O’Brien TD, Johnson KH, Seybold VS: Islet amyloid polypeptide (IAPP) competes for two binding sites of CGRP. Peptides 12:585–591, 1991.CrossRefGoogle Scholar
  69. 68.
    Morishita T, Yamaguchi A, Fujita T, Chiba T: Activation of adenylate cyclase by islet amyloid polypeptide with COOH-terminal amide via calcitonin gene-related peptide receptors on rat liver plasma membranes. Diabetes 39:875–877,1990.CrossRefGoogle Scholar
  70. 69.
    Kreutter D, Orena SJ, Torchia AJ, Contillo LG, Andrews GC, Stevenson RW: Amylin and CGRP induce insulin resistance via a receptor distinct from cAMP-coupled CGRP receptor. Am J Physiol 264:E606-E613, 1993.Google Scholar
  71. 70.
    Ohsawa H, Kanatsuka A, Yamaguchi T, Makino H, Yoshida S: Islet amyloid polypeptide inhibits glucose-stimulated insulin secretion from isolated rat pancreatic islets. Biochem Biophys Res Commun 160:961–967, 1989.CrossRefGoogle Scholar
  72. 71.
    Silvestre RA, Pieró E, Dégano P, Miralies P, Marco J: Inhibitory effect of rat amylin on the insulin responses to glucose and arginine in the perfused rat pancreas. Regul Pept 31:23–31, 1990.CrossRefGoogle Scholar
  73. 72.
    Wang Z-L, Bennet WM, Ghatei MA, Byfield PGH, Smith DM, Bloom SR: Influence of islet amyloid polypeptide and the 8–37 fragment of islet amyloid polypeptide on insulin release from perifused rat islets. Diabetes 42:330–335, 1993.CrossRefGoogle Scholar
  74. 73.
    Nagamatsu S, Carroll RJ, Grodsky GM, Steiner DF: Lack of islet amyloid polypeptide regulation of insulin biosynthesis or secretion in normal rat islets. Diabetes 39:871–874, 1990.CrossRefGoogle Scholar
  75. 74.
    Broderick CL, Brooke GS, DiMarchi RD, Gold G: Human and rat amylin have no effects on insulin secretion in isolated rat pancreatic islets. Biochem Biophys Res Commun 117:932–938, 1991.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Peter C. Butler
  • Norman L. Eberhardt
  • Timothy D. O’Brien

There are no affiliations available

Personalised recommendations